Actinic (Solar) Keratosis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Actinic (Solar) Keratosis – Pipeline Review, H2 2019’, provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis

– The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects

– The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AmDerma Pharmaceuticals LLC

Athenex Inc

G&E Corp

Gage Development Company LLC

Henderson Morley Plc (Inactive)

Laboratories Ojer Pharma SL

Nanology LLC

Neonc Technologies Inc

Oncology Research International Ltd

Pfizer Inc

Singh Biotechnology LLC

Vidac Pharma Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Actinic (Solar) Keratosis Overview

Actinic (Solar) Keratosis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Actinic (Solar) Keratosis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Actinic (Solar) Keratosis Companies Involved in Therapeutics Development

AmDerma Pharmaceuticals LLC

Athenex Inc

G&E Corp

Gage Development Company LLC

Laboratories Ojer Pharma SL

Nanology LLC

Neonc Technologies Inc

Novartis AG

Oncology Research International Ltd

Pfizer Inc

Promius Pharma LLC

Actinic (Solar) Keratosis Drug Profiles

854-A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFD-07 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-695 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-412 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORIL-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-300 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOR-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tuvatexib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Actinic (Solar) Keratosis Dormant Projects

Actinic (Solar) Keratosis Discontinued Products

Actinic (Solar) Keratosis Product Development Milestones

Featured News & Press Releases

Sep 18, 2018: DFB Soria completes a phase 2 clinical Trial of submicron particle Paclitaxel anhydrous ointment for actinic keratosis

Jul 26, 2018: Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints

Jul 10, 2018: Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis

Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting

Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis

Dec 18, 2017: NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers

Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting

Oct 12, 2017: Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis

Sep 26, 2017: DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)

Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis

Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion

Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis

Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment

Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Actinic (Solar) Keratosis – Pipeline by AmDerma Pharmaceuticals LLC, H2 2019

Actinic (Solar) Keratosis – Pipeline by Athenex Inc, H2 2019

Actinic (Solar) Keratosis – Pipeline by G&E Corp, H2 2019

Actinic (Solar) Keratosis – Pipeline by Gage Development Company LLC, H2 2019

Actinic (Solar) Keratosis – Pipeline by Henderson Morley Plc (Inactive), H2 2019

Actinic (Solar) Keratosis – Pipeline by Laboratories Ojer Pharma SL, H2 2019

Actinic (Solar) Keratosis – Pipeline by Nanology LLC, H2 2019

Actinic (Solar) Keratosis – Pipeline by Neonc Technologies Inc, H2 2019

Actinic (Solar) Keratosis – Pipeline by Oncology Research International Ltd, H2 2019

Actinic (Solar) Keratosis – Pipeline by Pfizer Inc, H2 2019

Actinic (Solar) Keratosis – Pipeline by Singh Biotechnology LLC, H2 2019

Actinic (Solar) Keratosis – Pipeline by Vidac Pharma Ltd, H2 2019

Actinic (Solar) Keratosis – Dormant Projects, H2 2019

Actinic (Solar) Keratosis – Dormant Projects, H2 2019 (Contd..1), H2 2019

Actinic (Solar) Keratosis – Dormant Projects, H2 2019 (Contd..2), H2 2019

Actinic (Solar) Keratosis – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports